ImmVirX
Australia - New Lambton HeightsBiotechnology
Focus: ImmVirX is an early-stage Australian biotechnology company focused on oncolytic virus development for cancer treatment. Founded in 2024, the company is in the discovery-to-early-development phase with minimal operational scale.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About ImmVirX
AI assessmentNot HiringNo open roles listed right now. Follow ImmVirX to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IVX037
Colorectal CancerClinical Trials (1)
NCT05427487Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1Help build intelligence for ImmVirX
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.